Ajanta Pharma in ‘Forbes Asia’s 200 Best under a Billion’ list

Ajanta Pharma, a Rs.900 crore plus specialty focused pharmaceutical formulation company from Mumbai, has featured among the ‘Forbes Asia’s 200 Best under a Billion’ list consecutively for the second year. It is indeed an important moment, as the company’s efforts have been recognized by a leading publication of world repute consistently for past 2 years as one of the best performing companies in Asia under a billion dollars. Only 19 Indian companies from various industries have been able to make to this prestigious compilation, including Ajanta.

Forbes Asia’s editors maintain a database of 15,000 stock-traded companies in Asia-Pacific region with revenues between $5 million and $1 billion. 873 companies were short listed and finally the top 200 companies were finalized. Only 52 companies from the last year’s list have re-qualified this year. Based on 3 stringent criteria of return on equity, growth in sales and earnings & debt-equity ratio, they selected 200 best performing companies and Ajanta is proud to be one amongst this elite list.

Commenting on this recognition, Yogesh Agrawal, managing director, said “The recognition is a testimony to Ajanta’s aligned, focused and committed efforts coupled with fundamentally strong strategies to build scalable and sustainable business model.”